[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"egpa---eosinophilic-granulomatosis-with-polyangiitis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:egpa---eosinophilic-granulomatosis-with-polyangiitis":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,40,62],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":21,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":39},"100614099","the-use-of-machine-learning-techniques-for-the-differential-diagnosis-between-eosinophilic-granulomatosis-with-polyangiitis-and-hypereosinophilic-syndrome-100614099",false,"NCT07275190","The Use of Machine Learning Techniques for the Differential Diagnosis Between Eosinophilic Granulomatosis With Polyangiitis and Hypereosinophilic Syndrome","Inclusion Criteria:\n\n1. 18 years of age or over\n2. A diagnosis of EGPA or HES\n3. Willing and able to give informed written consent, or willing to give permission for a nominated friend or relative to provide written informed assent if they are unable to do so because of physical disabilities\n\nExclusion Criteria:\n\n1. Lack of a confirmed diagnosis of EGPA or HES.\n2. Other causes of eosinophilia","ALL","18 Years",{"count":18,"type":19},60,"ESTIMATED","INTERVENTIONAL",[22],"NA","The purpose of this study is to collect clinical, laboratory, and instrumental data from patients with eosinophilic granulomatosis with polyangiitis or hypereosinophilic syndrome, which will then be analyzed using artificial intelligence techniques with the aim of identifying characteristics that differentiate the two diseases and can predict the response to the treatment plan.",[25,26],"EGPA - Eosinophilic Granulomatosis With Polyangiitis","HES - Hypereosinophilic Syndrome","RECRUITING","2025-11-28",{"date":30,"type":31},"2025-12-10","ACTUAL",{"date":33,"type":31},"2025-06-01",{"date":35,"type":19},"2026-12",{"name":37,"class":38},"Fondazione IRCCS Policlinico San Matteo di Pavia","OTHER",1,{"id":41,"slug":42,"hasResults":11,"nctId":43,"briefTitle":44,"officialTitle":45,"acronym":4,"eligibilityCriteria":46,"healthyVolunteers":47,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":48,"targetDuration":4,"studyType":50,"phases":4,"briefSummary":51,"conditions":52,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":53,"lastUpdatePostDateStruct":54,"startDateStruct":56,"completionDateStruct":58,"leadSponsor":60,"locationsCount":39},"100539023","egpa-and-local-inflammation-within-the-ear-nose-and-throat-area-100539023","NCT06298448","eGPA and Local Inflammation Within the Ear, Nose and Throat Area","Impact of Mepolizumab Treatment on the Nasal Microbiome and Local and Systemic Immune Response in Eosinophilic Granulomatosis With Polyangitis (eGPA)","Inclusion Criteria:\n\n* 18 years of age\n\n  * able to give informed consent\n  * In CRSwNP group: availability of bilateral nasal polyps as diagnosed by endoscopy or CT scan\n  * In Severe asthma group: clinical diagnosis of asthma with forced expiratory volume at one second(FEV1) \\\u003C80% AND either FEV1 reversibility \\>12% initial or documented positive metacholine challenge (PC20 \\\u003C 8 mg\u002Fml)\n  * In eGPA group: Fulfilling the 2022 ACR\u002FEULAR criteria for eGPA (Wechsler et al., 2017)\n  * In GPA group: fulfilling the American College of Rheumatology (ACR)\u002FEULAR GPA criteria (Robson et al., 2022)\n  * In healthy controls: absence of asthma symptoms, no bronchial hyperresponsiveness\n\nExclusion Criteria:\n\n* unable to give informed consent\n* Active smoking \\\u003C (less than) 6 months from baseline visit\n* Concomitant use of dupilumab within 6 months of baseline visit\n* pregnant or breastfeeding woman\n* in CRSwNP group: current use of asthma medication, eGPA\n* in healthy controls: chronic use of local anti-inflammatory agents\n* in healthy controls: use of immunosuppressive medication\n* in healthy controls: use of antibiotics within the last month (before start study\u002Fscreening\u002F)",true,{"count":49,"type":19},150,"OBSERVATIONAL","Rationale: Eosinophilic Granulomatosis with Polyangiitis (eGPA), eosinophilic asthma and chronic rhinosinusitis with nasal polyps (CRSwNP) are airway diseases where eosinophils and interleukine-5 are involved in the pathogenesis. eGPA differs from the other diseases with respect to involvement of other organs. The investigators hypothesize that nasal microbiome dysbiosis with a central augmenting role for S. Aureus plays an important role in disease expression. The investigators expect that anti-interleukin-5 treatment with mepolizumab restores the changes of the nasal microbiome and immune responses to a healthy control phenotype. To study this, the nasal microbiome, the local and systemic immune response and the effect of mepolizumab treatment will be assessed.",[25],"2024-02-29",{"date":55,"type":31},"2024-03-07",{"date":57,"type":31},"2024-02-14",{"date":59,"type":19},"2028-12",{"name":61,"class":38},"University Medical Center Groningen",{"id":63,"slug":64,"hasResults":11,"nctId":65,"briefTitle":66,"officialTitle":66,"acronym":67,"eligibilityCriteria":68,"healthyVolunteers":47,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":69,"targetDuration":71,"studyType":50,"phases":4,"briefSummary":72,"conditions":73,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":78,"startDateStruct":80,"completionDateStruct":82,"leadSponsor":84,"locationsCount":39},"100403869","prospective-registry-of-eosinophilia-with-respiratory-manifestations-with-translational-research-identifying-and-characterizing-eosinophils-100403869","NCT04538937","Prospective Registry of Eosinophilia With Respiratory Manifestations With Translational Research Identifying and Characterizing Eosinophils","PROMETHEos","Inclusion Criteria:\n\n* age ≥ 18 years\n* documented blood eosinophilia ≥ 300 cells\u002Fµl\n* present tissue damage of the respiratory tract caused by eosinophils\n\nExclusion Criteria:\n\n* age \\\u003C 18 years\n* pregnancy\n* dementia\n* incapacitated patients",{"count":70,"type":19},300,"10 Years","Introduction: The etiology and therapy of eosinophilic lung diseases are still poorly understood. For individual forms of disease, such as eosinophilic asthma or eosinophilic granulomatosis with polyangiitis (EGPA), new therapeutic approaches exist that block the interleukin IL-5 or the IL-5 receptor. Eosinophilic manifestations of the respiratory tract can exclusively affect the lungs or occur as part of a systemic disease. The manifestations partially overlap and are clinically difficult to differentiate (e.g. eosinophilic asthma, Samter Triad, EGPA or hypereosinophilic syndrome (HES)). It is now known that blood eosinophil counts correlate with the level of eosinophils recruited to the airways. However, it is still unclear whether there is a blood eosinophilia without clinical relevance or whether there is a risk of organ damage (e.g. in HES). Hence, different subtypes of eosinophils with different polarization are discussed.\n\nAim of the study: A registry of patients with eosinophilia and respiratory manifestation will be established at the University Hospital of Innsbruck. The course of disease will be evaluated prospectively in a non-interventional study. This study stands on three main clinical pillars with focus on further characterization of eosinophilic cells:\n\n1. Patients will be included who switch from a previous application of the anti-IL5 antibody mepolizumab (production and administration of the injection from lyophysate through the doctor) to the pre-mixed pen (self-injection at home).\n2. Furthermore, special focus is set on patients suffering from the so-called Samter Triad. In these patients, the control of asthma, nasal polyps and NSAID intolerance will be examined in an interdisciplinary fashion during the course of treatment.\n3. Previous clinical studies at our Department indicate that some patients with severe eosinophilic asthma or Samter Triad could represent a mono-organic or limited manifestation of lymphoid HES. This hypothesis is tested by measuring additional chemokines, somatic mutations and FACS parameters in this subgroup to verify a clonal disease.\n\nIn addition, translational research will differentiate resident and inflammatory eosinophilic granulocytes by FACS analysis and further characterize them by fluorescence microscopy, electron microscopy, gene chip analysis and lipidomics, in the above-mentioned diseases and in healthy controls, respectively.\n\nPatients and methods: All patients suffering from eosinophilia with pulmonary involvement who are diagnosed with eosinophilic asthma, EGPA, Samter Triad, HES, and eosinophilic pneumonia with signed consent are included in the prospective registry. Provided, that they are registered at the outpatient department of pneumology, ENT, haematology or allergology at the University Hospital Innsbruck. The investigators will collect laboratory analyses, lung function, imaging, bone marrow biopsies, ENT findings and allergological findings over the course of the study. Furthermore, additional blood tubes are collected during routine blood tests, which are used to identify and characterize subtypes of eosinophilic granulocytes.\n\nRisks for patients: No additional examinations, blood sampling or invasive measures are required for the patient. Thus, there is no additional risk for study participants.\n\nRisks for control subjects: In order to be able to compare our results with the healthy population, volunteer subjects are recruited. After consent has been given, a blood sample is taken. Despite the low risk, it is theoretically possible that blood sampling may be accompanied by non-severe complications (such as hematoma, infection).\n\nBenefits: The investigators expect new insights into phenotype and therapy of patients with eosinophilic manifestations of the respiratory tract.",[74,25,75,26,76],"Eosinophilic Asthma","Samter Triad","Eosinophilic Pneumonia","2020-09-02",{"date":79,"type":31},"2020-09-04",{"date":81,"type":31},"2020-02-26",{"date":83,"type":19},"2030-02-26",{"name":85,"class":38},"Medical University Innsbruck"]